Gilead Sciences

March 11, 2015March 11, 2015

Gilead Releases Phase 3 Results of Harvoni Study for HCV Genotype 4 Co-Infected with HIV

News

Gilead Sciences, a company focused on delivering treatments for patients with a wide range of diseases including Hepatitis C, recently announced the results from its Phase 3 study called ION-4, a ... Read more

March 5, 2015March 6, 2015

Gilead Hands Over Sofosbuvir Distribution in India to Mylan

Hepatitis C, News

The Indian subsidiary of Mylan Inc. has signed an agreement with biopharmaceutical company Gilead Sciences to receive the rights as exclusive distributor in India of both Sovaldi and Harvoni — therapies designed to treat ... Read more

March 3, 2015March 3, 2015

HBV Patients With Nucleotide Analogue Resistance May Benefit from TDF Monotherapy

Hepatitis B, News

Recent research reports that tenofovir disoproxil fumarate (TDF) therapy for long periods is efficient in Chinese patients with chronic hepatitis B virus (HBV) infection that have relapsed after therapy with multiple ... Read more

February 24, 2015February 24, 2015

Recent Findings on Hepatitis C RNA Structure May Contribute to Discovery of New Treatments

Hepatitis C, News

A research team at Gilead Sciences recently determined the x-ray crystal structure of the Hepatitis C virus (HCV) RNA polymerase while assembled with the other components of the RNA replication machinery, as ... Read more

February 2, 2015February 2, 2015

Sofosbuvir-Ribavirin Prevent HCV Recurrence After Transplantation

Hepatitis C, News

Two new studies on the hepatitis C virus entitled “Sofosbuvir and Ribavirin Prevent Recurrence of HCV Infection after Liver Transplantation: An Open-Label Study” and “Sofosbuvir and Ribavirin for Treatment of ... Read more

January 26, 2015January 26, 2015

Gilead’s Hepatitis C Treatment Sofosbuvir Rejected in India

News

Gilead Sciences, Inc.‘s application to commercialize novel hepatitis C treatment sofosbuvir in India has been rejected by the country’s patent office, as reported by Reuters. The refusal may open a new ... Read more

January 22, 2015January 22, 2015

Gilead Sciences Acquires Phenex Pharma’s Platform for Non-Alcoholic Steatohepatitis

News

Gilead Sciences, Inc. and Phenex Pharmaceuticals AG, announced the establishment of a contract in which Gilead is set to acquire the Farnesoid X Receptor (FXR) program of Phenex for the application of small molecule FXR agonists to treat liver ... Read more

December 10, 2014December 10, 2014

Lawsuit Against Gilead Sciences High Prices For Sovaldi In The U.S.

Hepatitis C, News

A lawsuit was recently filed by a Philadelphia-area law firm against Gilead Sciences, Inc. (“Gilead”) on behalf of the Southeastern Pennsylvania Transportation Authority (“SEPTA”) due to the sale and pricing of Sovaldi®, Gilead’s groundbreaking Hepatitis C drug. Sovaldi is ... Read more

November 21, 2014November 21, 2014

First Oral Combination Drug for Hep C Approved in Europe

Hepatitis C, News

Gilead Sciences, Inc. recently announced that the European Commission has finally granted marketing authorization for their novel hepatitis C treatment Harvoni® (ledipasvir 90 mg/sofosbuvir 400 mg), which is the first and only once-a-day ... Read more

October 30, 2014October 30, 2014

Australia Declines to Subsidize Hepatitis C Drug Therapy Sofosbuvir

Hepatitis C, News

The drug Sofosbuvir, for the treatment of hepatitis C, produced by Gilead Sciences, will not be subsidized by the Australian government, due to its costs. The Pharmaceutical Benefits Advisory Committee (PBAC) announced that ... Read more